Long-term outcomes of adult pulmonary Langerhans cell histiocytosis: a prospective cohort.
Amira Benattia, Emmanuelle Bugnet, Anouk Walter-Petrich...
https://pubmed.ncbi.nlm.nih.gov/34675043Actively Recruiting
Age: 18Years +
All Genders
ID04665674
Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study in France
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2020-12-17
500
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying adult patients with pulmonary Langerhans cell histiocytosis (PLCH) to understand their long-term outcomes, especially survival rates. This is the first prospective national study using a large registry of PLCH patients in France, followed over many years to identify risk factors affecting their prognosis. The study is observational and aims to provide valuable information on the disease course in adults. Participants include adults aged 18 years or older who have been newly diagnosed with PLCH. Diagnosis is confirmed either by biopsy or through a combination of clinical signs, specific lung imaging patterns on high-resolution CT scans, and ruling out other diseases. Patients receive standard care for PLCH as part of the study. During the study, researchers will monitor overall survival over 20 years as the main outcome. They will also track additional health data including clinical report forms, pulmonary hypertension, occurrence of malignant diseases, involvement beyond the lungs, and yearly disease prevalence. This long-term follow-up helps to understand the disease progression and patient health over time.
CONDITIONS
Brief Title
Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Age �3E�3D 18 years
- Diagnosis of PLCH confirmed by biopsy or based on clinical picture with typical nodulo-cystic lung pattern on HRCT and exclusion of other diagnoses
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 20 years
Participants who undergo routine care for pulmonary Langerhans cell histiocytosis (PLCH) are observed to collect data on survival and disease progression over time.
Annual visits for up to 20 years
Trial Site Locations
Total: 1 location
1
French national reference centre for Histiocytoses
Paris, France, 75010
Actively Recruiting
Loading map...
Research Team
A
Abdellatif TAZI, MD PhD
M
matthieu resche-rigon, MD PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here